FDA Orange Book · active-ingredient family
Peramivir
Peramivir is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:RAPIVAB · NDA 206426
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| RAPIVABRLD | BIOCRYST | NDA 206426 | — | Dec 19, 2014 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10391075 | Feb 12, 2027 | in 8 mo | U-2622 |
| 8778997 | May 07, 2027 | in 11 mo | U-2622 |
Peramivir — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
